AUS
NZ
UK
CA
USA
IND
Highlights
- Mayne Pharma expects up to $215 million in revenue for 1H25.
- Projected EBITDA increase of nearly 300% year-on-year.
- Focus on Women’s Health and Dermatology driving growth.
Mayne Pharma (ASX:MYX) is forecasting strong financial performance for the first half of the 2025 financial year, with revenue expectations ranging between $210 million and $215 million. This marks a promising growth of approximately 14% compared to the same period last year. The company’s impressive revenue outlook underscores the momentum it has been building, driven by its strategic focus on key segments such as Women’s Health and Dermatology.
The anticipated surge in earnings before interest, taxes, depreciation, and amortization (EBITDA) is equally remarkable. Mayne Pharma expects to report an underlying EBITDA between $30 million and $32 million, a significant increase of nearly 300% from the previous year. This growth reflects the company’s ability to scale operations effectively while maintaining a solid revenue base.
Mayne Pharma's CEO, Shawn Patrick O’Brien, expressed confidence that this positive trend would continue. "We have experienced solid trading conditions in the first half as we execute against our corporate strategies, with robust revenue growth recorded, particularly within our Women’s Health segment," he stated. The company is leveraging its core business segments to drive operational efficiency and profitability.
In addition to strong growth in revenue and EBITDA, Mayne Pharma is also anticipating some seasonal cost impacts. These are related to patient payment programs, with deductible resets, as well as increased promotional expenses for its Women’s Health products aimed at boosting additional revenue generation. Despite these costs, the company remains confident in its ability to continue driving growth across its key segments.
As of the end of December, Mayne Pharma reported cash and marketable securities totaling $124.9 million, a slight decrease of $4.6 million compared to October. The company’s balance sheet reflects its commitment to maintaining a conservative capital structure while pursuing future growth opportunities.
Chairman Frank Cordella emphasized the company’s focus on operational excellence and growth. "Management is focused on delivering operational excellence and achieving our growth goals," he said, noting that the board will continue to explore complementary partnerships or acquisitions to enhance its existing Women’s Health and Dermatology portfolios.
With a strategic focus on improving infrastructure and operational efficiencies, Mayne Pharma is positioning itself for continued success in the coming years.
